Trials / Terminated
TerminatedNCT01263028
Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Kaiser Permanente · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a nonanemic state.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ergocalciferol supplementation | Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D. |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-12-20
- Last updated
- 2015-03-30
- Results posted
- 2012-09-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01263028. Inclusion in this directory is not an endorsement.